Human respiratory syncytial virus antibodies and methods of use therefor
AssigneeVanderbilt University
InventorsJames E. Crowe, Jr., Jarrod Mousa
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
Claims26
A method of detecting a human respiratory syncytial virus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) detecting human respiratory syncytial virus in said sample by binding of said antibody or antibody fragment to a Human respiratory syncytial virus antigen in said sample.
2-12. (canceled)
A method of treating a subject infected with human respiratory syncytial virus, or reducing the likelihood of infection of a subject at risk of contracting human respiratory syncytial virus, comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
26-35. (canceled)
A hybridoma or engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
37-46. (canceled)
A vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
48-52. (canceled)
(canceled)
A method of identifying an anti-human respiratory syncytial virus (hRSV) protein F site II-specific neutralizing antibody comprising:
- (a) contacting a candidate antibody with hRSV protein F in the presence of a known site II-specific neutralizing antibody or antigen binding fragment thereof;
- (b) assessing binding of said candidate antibody to hRSV protein F;
- and
- (c) identifying said candidate antibody as a protein F site II-specific neutralizing antibody when said known site II-specific neutralizing antibody or antigen binding fragment thereof blocks binding of said candidate antibody to hRSV protein F.
58-66. (canceled)
Dependencies are inferred from the claim text.